D. E. Shaw & Co. Inc. Sells 336,949 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

D. E. Shaw & Co. Inc. lessened its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 46.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 387,733 shares of the company's stock after selling 336,949 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.52% of SpringWorks Therapeutics worth $14,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of SWTX. Los Angeles Capital Management LLC lifted its position in shares of SpringWorks Therapeutics by 30.8% during the 4th quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company's stock valued at $2,231,000 after buying an additional 14,548 shares during the last quarter. Schroder Investment Management Group lifted its position in shares of SpringWorks Therapeutics by 93.6% during the 4th quarter. Schroder Investment Management Group now owns 168,209 shares of the company's stock valued at $6,113,000 after buying an additional 81,314 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of SpringWorks Therapeutics by 6.6% during the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after buying an additional 445,593 shares during the last quarter. BIT Capital GmbH lifted its position in shares of SpringWorks Therapeutics by 18.7% during the 4th quarter. BIT Capital GmbH now owns 53,539 shares of the company's stock valued at $1,934,000 after buying an additional 8,429 shares during the last quarter. Finally, Platinum Investment Management Ltd. purchased a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at $1,694,000.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ:SWTX traded up $0.03 on Friday, hitting $46.11. The company's stock had a trading volume of 7,025,072 shares, compared to its average volume of 2,099,792. The company has a 50-day simple moving average of $43.95 and a 200 day simple moving average of $42.16. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The company has a market capitalization of $3.46 billion, a PE ratio of -13.25 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The business had revenue of $49.09 million during the quarter, compared to analysts' expectations of $64.19 million. On average, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Buying and Selling at SpringWorks Therapeutics

In other news, CEO Saqib Islam sold 29,328 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $60.30, for a total transaction of $1,768,478.40. Following the transaction, the chief executive officer now directly owns 1,034,625 shares in the company, valued at approximately $62,387,887.50. This represents a 2.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bhavesh Ashar sold 1,016 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. This trade represents a 1.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 146,944 shares of company stock valued at $8,439,479 in the last 90 days. Corporate insiders own 7.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Cowen cut SpringWorks Therapeutics to a "hold" rating in a report on Tuesday, April 29th. Guggenheim reissued a "neutral" rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, May 12th. HC Wainwright reissued a "neutral" rating and set a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Finally, Barclays reissued an "equal weight" rating and set a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $52.57.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.